FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

	Washingto	in, D.C. 20549	
STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			or S	ection 30(h) of the I	nvestment Co	npany Act of 1940				
1. Name and Address of Reporting Person* O'NEIL PATRICK R. (Last) (First) (Middle) C/O ISIS PHARMACEUTICALS, INC. 2855 GAZELLE COURT		3. Da	suer Name and Tick S PHARMAC atte of Earliest Transa 9/2014	EUTICĂ:	LS INC [ISIS]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below) SVP, Legal and General Counsel				
-			4. If A	Amendment, Date of	f Original Filed	(Month/Day/Year)	6. Indiv	vidual or Joint/Grou	up Filing (Check	Applicable
(Street) CARLSBAD	CA	92010					X	•	ne Reporting Per ore than One Re	
(City)	(State)	(Zip)						. 0.00		
		Table I - Non-D	erivative	Securities Aco	uired, Dis	posed of, or Benef	icially	Owned		
4 Title of Committee	<i>a</i>	l a =		Ta. 5 .					1.0	1

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 are)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)						
			Code	v	Amount	(A) or Price		Transaction(s) (Instr. 3 and 4)		(111501.4)		
Common Stock	06/19/2014	06/19/2014	M ⁽¹⁾		33(1)	A	\$8	3,383	D			
Common Stock	06/19/2014	06/19/2014	S ⁽¹⁾		33(1)	D	\$35.27	3,350	D			
Common Stock	06/19/2014	06/19/2014	M ⁽¹⁾		300(1)	A	\$10.29	3,650	D			
Common Stock	06/19/2014	06/19/2014	S ⁽¹⁾		300(1)	D	\$35.45	3,350	D			
Common Stock	06/19/2014	06/19/2014	M ⁽¹⁾		200(1)	A	\$10.29	3,550	D			
Common Stock	06/19/2014	06/19/2014	S ⁽¹⁾		200(1)	D	\$35.29	3,350	D			
Common Stock	06/19/2014	06/19/2014	M ⁽¹⁾		100(1)	A	\$10.29	3,450	D			
Common Stock	06/19/2014	06/19/2014	S ⁽¹⁾		100(1)	D	\$35.275	3,350	D			
Common Stock	06/19/2014	06/19/2014	M ⁽¹⁾		67(1)	A	\$10.29	3,417	D			
Common Stock	06/19/2014	06/19/2014	S ⁽¹⁾		67(1)	D	\$35.27	3,350	D			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Employee Stock Option (right to buy)	\$8	06/19/2014	06/19/2014	M			33	09/01/2011 ⁽²⁾	08/31/2017	Common Stock	33	\$0	1,667	D	
Employee Stock Option (right to buy)	\$10.29	06/19/2014	06/19/2014	M			667	01/03/2012 ⁽³⁾	01/02/2018	Common Stock	667	\$0	10,483	D	

Explanation of Responses:

- 1. Acquired as a result of exercising a stock option pursuant to a Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/2/14.
- 2. Grant of 9/1/10 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vest and became exercisable on 9/1/11. Thereafter, the remaining shares subject to the option vest and became exercisable in 36 equal monthly installments, at the rate of 2,500 shares per year. The option shall be fully vested and exercisable on 9/1/14. The option, before the reported exercises, was exercisable as to 1,700 shares on 6/19/14.
- 3. Grant of 1/3/11 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vest and became exercisable on 1/3/12. Thereafter, the remaining shares subject to the option vest and became exercisable in 36 equal monthly installments, at the rate of 5,750 shares per year. The option shall be fully vested and exercisable on 1/3/15. The option, before the reported exercises, was exercisable as to 11,150 shares on 6/19/14.

Remarks:

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.